WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026

Summary

Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoYAdjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 BillionBacklog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI, April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first quarter ending March 31, 2026 ('Reporting Period'): Total revenue reached RMB 12.44 billion, up 28.8% YoY; revenue from Continuing Operations up 39.4% YoY.Adjusted non-IFRS gross profit margin up 8.5pts YoY to 50.4%.Adjusted non-IFRS net profit up 71.7% YoY to RMB 4.60 billion; adjusted non-IFRS net profit margin up 9.2pts YoY to 37.0%; adjusted non-IFRS diluted EPS[1] up 67.0% YoY to RMB 1.57.Net profit[2] up 26.7% YoY to RMB 4.65 billion; diluted EPS up 23.4% YoY to RMB 1.58.Backlog for Continuing Operations reached RMB 59.77 billion as of March 31,2026, up 23.6% YoY, as we continue to focus on our core CRDMO strategy and further enhance business visibility. Adjusted operating cash flow[3] up 21.7% YoY to RMB 3.69 billion, driven by sustained business growth, enhanced operational efficiency and financial management.Sustained and steady business growth driven by our unique, fully integrated CRDMO platform. Guided by 'follow the molecule' and 'win the molecule' strategies, WuXi Chemistry's small molecule CRDMO pipeline continues to efficiently convert and capture high-quality molecules, delivering sustained business growth. In the first quarter of 2026, we added 328 new molecules to the small molecule Development and Manufacturing (D&M) pipeline. As of March 31, 2026, our small molecule D&M pipeline reached 3,550 molecules, representing an increase of 9 projects in phase III and commercial stages in the first quarter of 2026.The Company reaffirms its full-year guidance with strong confidence. We are closely monitoring market dynamics and business development, and will raise guidance when appropriate.[1] In Q1 2025 and Q1 2026, WuXi AppTec had a fully-diluted weighted average share count of 2,899,579,930 and 2,934,223,680 ordinary shares, respectively.[2] Net profit attributable to the owners of the Company ('Net Profit') is prepared in accordance with China Accounting Standards for Business Enterprises ('CAS').[3] Adjusted operating cash flow excludes income tax payments related to significant transactions (i.e., the sale of the China-based clinical research service businesses) disclosed in the Company's announcements.Management Comment

Description

Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoYAdjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 BillionBacklog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI, April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first quarter ending March 31, 2026 ('Reporting Period'): Total revenue reached RMB 12.44 billion, up 28.8% YoY; revenue from Continuing Operations up 39.4% YoY.Adjusted non-IFRS gross profit margin up 8.5pts YoY to 50.4%.Adjusted non-IFRS net profit up 71.7% YoY to RMB 4.60 billion; adjusted non-IFRS net profit margin up 9.2pts YoY to 37.0%; adjusted non-IFRS diluted EPS[1] up 67.0% YoY to RMB 1.57.Net profit[2] up 26.7% YoY to RMB 4.65 billion; diluted EPS up 23.4% YoY to RMB 1.58.Backlog for Continuing Operations reached RMB 59.77 billion as of March 31,2026, up 23.6% YoY, as we continue to focus on our core CRDMO strategy and further enhance business visibility. Adjusted operating cash flow[3] up 21.7% YoY to RMB 3.69 billion, driven by sustained business growth, enhanced operational efficiency and financial management.Sustained and steady business growth driven by our unique, fully integrated CRDMO platform. Guided by 'follow the molecule' and 'win the molecule' strategies, WuXi Chemistry's small molecule CRDMO pipeline continues to efficiently convert and capture high-quality molecules, delivering sustained business growth. In the first quarter of 2026, we added 328 new molecules to the small molecule Development and Manufacturing (D&M) pipeline. As of March 31, 2026, our small molecule D&M pipeline reached 3,550 molecules, representing an increase of 9 projects in phase III and commercial stages in the first quarter of 2026.The Company reaffirms its full-year guidance with strong confidence. We are closely monitoring market dynamics and business development, and will raise guidance when appropriate.[1] In Q1 2025 and Q1 2026, WuXi AppTec had a fully-diluted weighted average share count of 2,899,579,930 and 2,934,223,680 ordinary shares, respectively.[2] Net profit attributable to the owners of the Company ('Net Profit') is prepared in accordance with China Accounting Standards for Business Enterprises ('CAS').[3] Adjusted operating cash flow excludes income tax payments related to significant transactions (i.e., the sale of the China-based clinical research service businesses) disclosed in the Company's announcements.Management Comment

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage